AN-788
AN-788, also known as NSD-788, is an experimental medication which was originated by NeuroSearch and is under development by Aniona and Saniona for the treatment of major depressive disorder.[1][2][3] It was also under development for anxiety disorders, but development for this indication was discontinued.[1] The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI).[1][2][3] As of November of 2018, it is in an agreement for phase II clinical trials for major depressive disorder.[4]
| Clinical data | |
|---|---|
| Other names | NSD-788 |
| Drug class | Monoamine reuptake inhibitor; Serotonin–dopamine reuptake inhibitor |
| Identifiers | |
| CAS Number | |
References
- "Initiator Pharma".
- Shao L, Li W, Xie Q, Yin H (2014). "Triple reuptake inhibitors: a patent review (2006 - 2012)". Expert Opin Ther Pat. 24 (2): 131–54. doi:10.1517/13543776.2014.859676. PMID 24289044. S2CID 1825304.
- Gerhard F. Ecker; Rasmus P. Clausen; Harald H. Sitte (16 December 2016). Transporters as Drug Targets. Wiley. pp. 36–. ISBN 978-3-527-67951-5.
- "Initiator Pharma signs option agreement for Phase 2 ready drug candidate". News Powered by Cision. Retrieved 2022-02-08.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.